Core Viewpoint - The strategic cooperation agreement between the company and Eli Lilly for drug development in oncology and immunology has been approved and is now effective as of March 24, 2026 [1] Group 1: Strategic Cooperation Agreement - The company announced the signing of a strategic cooperation agreement with Eli Lilly to advance new drug development in oncology and immunology [1] - The agreement has received early approval from the Federal Trade Commission, fulfilling all conditions for its effectiveness [1] - The strategic cooperation agreement officially became effective on March 24, 2026 [1] Group 2: Clarification on Misinterpretations - The company clarified that some media reports incorrectly interpreted the effectiveness of the strategic cooperation agreement as an acquisition of the company [1] - The company emphasized that it has no intention of engaging in any acquisition transactions [1] - Shareholders and potential investors are advised not to rely on market rumors and should refer only to the company's official announcements for information [1]
信达生物(01801.HK)与礼来制药合作协议所有先决条件已达成 澄清非收购交易